menu
    • menu
    [{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"pharmtrace","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ pharmtrace","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ pharmtrace"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"pharmtrace klinische Entwicklung","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Florbetaben","moa":"Amyloid-beta-plaque","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ pharmtrace klinische Entwicklung","highestDevelopmentStatusID":"10","companyTruncated":"Life Molecular Imaging \/ pharmtrace klinische Entwicklung"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Life Molecular Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"18-F PI2620","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ Life Molecular Imaging","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Life Molecular Imaging"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F PI2620","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Walter Reed National Military Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F PI-2620","moa":"Tau aggregation","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Walter Reed National Military Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Walter Reed National Military Medical Center"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F PI-2620","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Life Molecular Imaging \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Life Molecular Imaging

    Menu

    Life Molecular Imaging

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : pharmtrace

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Test-retest Study With [18F]FBB in Cardiac Amyloidosis

                            Details : Florbetaben is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 24, 2025

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : pharmtrace

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F PI-2620

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            [18F]PI-2620 Phase 3 Histopathological Study

                            Details : 18-F PI-2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            December 08, 2022

                            Lead Product(s) : 18-F PI-2620

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F PI-2620

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Walter Reed National Military Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain ...

                            Details : 18-F PI-2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Concussion.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            April 20, 2022

                            Lead Product(s) : 18-F PI-2620

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Walter Reed National Military Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F PI2620

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

                            Details : 18-F PI2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Supranuclear Palsy, Progressive.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 12, 2022

                            Lead Product(s) : 18-F PI2620

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F Florbetaben

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : pharmtrace klinische Entwicklung

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

                            Details : 18-F Florbetaben is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 11, 2022

                            Lead Product(s) : 18-F Florbetaben

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : pharmtrace klinische Entwicklung

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Life Molecular Imaging

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F PI2620

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Life Molecular Imaging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific A...

                            Details : 18-F PI2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 20, 2021

                            Lead Product(s) : 18-F PI2620

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Life Molecular Imaging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth